Vascular endothelial growth factor and pigment epithelial-derived factor in the peripheral response to ketamine

McGrory, Claire L.; Ryan, Karen M.; Gallagher, Bronagh; McLoughlin, Declan M.

doi:10.1016/j.jad.2020.04.013

Cited by 14 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF also appeared to be critical for the behavioral effects of various antidepressants ( 20 , 34 , 35 ) and lamotrigine ( 36 ) in rodent models of depression. In a recent clinical study, a single infusion of ketamine increased the plasma mRNA levels of VEGF, supporting a role for VEGF in the action of ketamine ( 25 ). However, our data failed to demonstrate that plasma VEGF concentrations were significantly associated with ketamine's rapid antianhedonic effects in subjects with TRD.…”

Section: Discussionmentioning

confidence: 89%

“…Similarly, serum BDNF levels were increased in chronic ketamine users (21) and change in plasma BDNF levels following subanesthetic ketamine infusion are associated with acute and 24 h resting-state functional connectivity (RSFC) changes (22). Findings on the association of VEGF and ketamine's antidepressant effects have been inconsistent (18,(23)(24)(25). For example, the expression of VEGF is necessary for the antidepressant-like behaviors of ketamine (18,19).…”

Section: Introductionmentioning

confidence: 99%

“…For example, the expression of VEGF is necessary for the antidepressant-like behaviors of ketamine (18,19). A recent study supported a role for VEGF in the antidepressant action of ketamine (25), but two recent studies found that ketamine does not change the plasma concentrations of VEGF (23,24). However, evidence on the role of plasma VEGF concentrations in ketamine's antianhedonic effects is still lacking.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

Zheng

Zhou

et al. 2021

Front. Psychiatry

View full text Add to dashboard Cite

Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) anhedonia item at baseline, day 13 and 26. Plasma VEGF concentrations were examined at the same time points as the MADRS.Results: Despite a significant reduction in anhedonia symptoms in individuals with treatment-refractory MDD (n = 59) or BD (n = 19) after they received repeated-dose ketamine infusions (p < 0.05), no significant changes in plasma VEGF concentrations were found at day 13 when compared to baseline (p > 0.05). The alteration of plasma VEGF concentrations did not differ between antianhedonic responders and non-responders at days 13 and 26 (all ps > 0.05). Additionally, no significant correlations were observed between the antianhedonic response to ketamine and plasma VEGF concentrations (all ps > 0.05).Conclusion: This preliminary study suggests that the antianhedonic effects of ketamine are not mediated by VEGF.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

Zheng

Zhou

et al. 2021

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Descriptive and comparative statistics were performed using IBM SPSS Statistics, version 24.0 (IBM Corp, Armonk, NY). We initially planned to recruit 40 participants (20 per group) to also allow for some biomarker research 39 . However, recruitment ended earlier than expected when 25 participants had been enrolled in good time, demonstrating that a larger definitive trial was clearly feasible.…”

Section: Discussionmentioning

confidence: 99%

“…The QIDS-16 SR scores followed a similar pattern to the HRSD-24 scores, as shown in Figure 4 and Figure 5. Data relating to the very first infusion sessions have been previously reported on in a study examining peripheral blood molecular changes related to ketamine 39 .…”

Section: Participantsmentioning

confidence: 99%

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Depression is a common psychiatric disorder that has become the leading cause of disability worldwide. The standard medical care for depression over the past 50 years has focused on monoamine neurotransmitters. These treatments can take weeks to take effect, highlighting the need for novel treatment strategies. One such approach may be ketamine. Ketamine acts as an antagonist of the N-methyl-D-asparate receptor and thus targets the excitatory amino acid neurotransmitter glutamate. Interestingly, at sub-anaesthetic doses, a single infusion of ketamine can elicit a rapid, though transient, antidepressant response. Methods: The aim of this study was to conduct a pragmatic randomised controlled pilot trial of four once-weekly ketamine infusions as an adjunctive therapy for depression. The main objective was to assess trial procedures to inform a future definitive trial. The primary clinical outcome was the 24-item Hamilton Rating Scale for Depression (HRSD-24). Trial participants were patients admitted to St Patrick’s Mental Health Services for treatment of a depressive episode. They underwent usual inpatient care as prescribed by their treating team. Consented participants were randomly allocated to a four-week course of either once-weekly ketamine (0.5mg/kg) or midazolam (0.045mg/kg) infusions given over 40 minutes and with 12 weeks follow-up. Results: In total, 1581 admissions to St Patrick’s Hospital were assessed for eligibility over nine months, with 125 (8%) meeting criteria, with 25 (20%) providing consent. In total, 13 were randomly assigned to the ketamine arm and 12 to the midazolam arm. There were no major differences in HRSD-24 scores between the two groups. The infusions were generally safe and well tolerated. Conclusions: This is the first pragmatic pilot trial of adjunctive serial ketamine infusions for hospitalised depression, an important possible use of ketamine. This study suggests that a definitive trial of adjunctive ketamine is feasible. Trial registration: ClinicalTrials.gov NCT03256162 21/08/2017; EudraCT 2016-004764-18 30/11/2016.

show abstract

The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials

Rossi

Hallak

Baker

et al. 2022

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Vascular endothelial growth factor and pigment epithelial-derived factor in the peripheral response to ketamine

Cited by 14 publications

References 17 publications

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials

Contact Info

Product

Resources

About